

SLEEP DISTURBANCE IN ADT RECIPIENTS

Supplementary Table 1

Control Groups Did Not Differ on Sleep Outcomes, Nocturia, or Hot Flash Interference

Outcome	Sample Size	ADT-	CA-	ADT- vs. CA-
	n	<i>M</i> (<i>SD</i>)	<i>M</i> (<i>SD</i>)	<i>p</i>
Sleep Efficiency	68	80.56 (7.92)	78.98 (8.16)	.42
Wake After Sleep Onset	68	55.00 (23.68)	52.91 (19.92)	.70
Sleep Onset Latency	68	20.04 (28.24)	26.25 (27.92)	.37
Sleep Duration	68	436.76 (64.35)	431.74 (73.71)	.77
Nocturia	68	1.41 (0.99)	1.49 (1.25)	.78
Outcome	n	<i>M</i> (<i>SE</i>)	<i>M</i> (<i>SE</i>)	<i>p</i>
Subjective Sleep Disturbance	207	5.33 (0.43)	5.13 (0.47)	.76
Hot Flash Interference	207	0.93 (0.40)	0.36 (0.18)	.18

Note. ADT- = prostate cancer patients not treated with ADT; CA- = men with no history of prostate cancer; *M* = mean; *SD* = standard deviation; *SE* = standard error.

SLEEP DISTURBANCE IN ADT RECIPIENTS

Supplementary Table 2

Unadjusted Group Means for Sleep Outcomes, Nocturia, and Hot Flash Interference

	Sample Size	ADT+	Controls
	n	<i>M (SD)</i>	<i>M (SD)</i>
Sleep Efficiency	100	75.07 (13.26)	79.82 (8.00)
Wake After Sleep Onset	100	73.49 (34.19)	54.01 (21.85)
Sleep Onset Latency	100	32.89 (47.24)	22.96 (26.05)
Sleep Duration	100	447.54 (98.59)	434.40 (68.43)
Nocturia	99	3.33 (2.15)	1.45 (1.12)
Subjective Sleep Disturbance	226	9.84 (7.45)	5.25 (5.02)
Hot Flash Interference	224	14.91 (20.16)	0.41 (3.16)

Note. ADT+ = prostate cancer patients treated with ADT; SD = standard deviation. Covariate-adjusted *p* values controlling for baseline medical comorbidities were calculated using ANCOVA analyses.